On Location

On Location

Updates from major medical meetings in the field of hematology/oncology

Can Biomarkers Predict Myeloma Patients’ Response to Venetoclax?

In an analysis of the phase III BELLINI trial, researchers identified 2 biomarkers that predict response to venetoclax in patients with relapsed/refractory multiple myeloma...

Acalabrutinib Treatment Superior to Obinutuzumab Plus Chlorambucil in Treatment-Naïve Chronic Lymphocytic Leukemia

Acalabrutinib, alone or combined with obinutuzumab, led to greater improvements in progression-free survival (PFS), compared with obinutuzumab plus chlorambucil, in patients with treatment-naïve chronic...

ER-Based Protocol Improves the Accuracy of von Willebrand Disease Testing in Young Patients With...

Watch our interview with Megan C. Brown, MD. Researchers at Children’s Healthcare of Atlanta (CHOA) have developed an emergency department (ED)–based protocol that helps standardize...

Decitabine Maintenance May Improve Survival in Older Patients With AML

One year of maintenance therapy with brief monthly courses of intravenous decitabine was associated with improved overall survival (OS) among older patients with acute...

Perspectives on 2019’s New Hematology Drug Approvals

In 2019, the FDA approved several new therapies – or new indications for previously approved therapies – for people living with blood disorders, including...

Updates on ASH Clinical Practice Guidelines in Development

In 2019, the American Society of Hematology (ASH) continued its efforts to develop and publish evidence-based clinical practice guidelines to help practicing hematologists and...

Time-Limited Acalabrutinib Combination Has “Encouraging” Response Rates in Previously Untreated Chronic Lymphocytic Leukemia

Watch our interview with Benjamin Lampson, MD. Preliminary results from a trial presented at the 2019 ASH Annual Meeting suggest that time-limited frontline therapy for...

Adding Navitoclax to Ruxolitinib in Ruxolitinib-Refractory Myelofibrosis Leads to Improvements in Spleen Volume, Symptom...

Watch our interview with Jacqueline Garcia, MD. More than one-third of patients with myelofibrosis (MF) who had not responded adequately to monotherapy with the FDA-approved...

KTE-X19: A CAR T-Cell Option for Mantle Cell Lymphoma?

According to results from the ZUMA-2 trial presented at the 2019 ASH Annual Meeting, 93% of patients with relapsed/refractory mantle cell lymphoma (MCL) responded...

Early-Phase Trial Shows Mosunetuzumab Induces Durable Complete Remissions in Patients With B-Cell Non-Hodgkin...

Watch our interview with Stephen J. Schuster, MD. The bispecific monoclonal antibody mosunetuzumab, which binds to CD3 and CD20, led to durable responses in patients...
Advertisement

Current Issue

February 2020, Volume 6, Issue 3

This issue examines the high price of treating hemophilia, asks whether CAR T-cell therapies are worth the cost, and more.